| 前收市價 | 1.7600 |
| 開市 | 1.8100 |
| 買盤 | 1.7600 x 100 |
| 賣出價 | 1.8200 x 100 |
| 今日波幅 | 1.7600 - 1.8400 |
| 52 週波幅 | 1.6200 - 5.7000 |
| 成交量 | |
| 平均成交量 | 336,348 |
| 市值 | 122.788M |
| Beta 值 (5 年，每月) | -0.37 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.7500 |
| 業績公佈日 | 2024年5月09日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 14.69 |
ZacksWhy You Shouldn't Bet Against Vor Biopharma (VOR) Stock
Vor Biopharma (VOR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
BenzingaVor Bio's Trem-cel Shows Early Encouraging Data In Leukemia Patients
Vor Biopharma Inc (NASDAQ: VOR) presented updated data from patients treated in the VBP101 Phase 1/2a study of trem-cel (formerly VOR33) in acute myeloid leukemia patients. The time for neutrophil engraftment in all five patients treated with trem-cel (10-11 days) was similar to unedited transplants. All patients achieved high levels of myeloid donor chimerism by day 28. After achieving timely neutrophil engraftment and platelet recovery, patient 2 experienced secondary graft failure coincident
